Avidity Biosciences - RNA Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RNA shares.
View RNA analyst ratings or view top-rated stocks.

5 brokerages have issued 1 year target prices for Avidity Biosciences' shares. Their RNA share price forecasts range from $27.00 to $71.00. On average, they predict the company's share price to reach $43.60 in the next year. This suggests a possible upside of 184.0% from the stock's current price.
View analysts price targets for RNA or view top-rated stocks among Wall Street analysts.

Avidity Biosciences' stock was trading at $22.19 at the start of the year. Since then, RNA stock has decreased by 30.8% and is now trading at $15.35.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our RNA earnings forecast.

Avidity Biosciences, Inc. (NASDAQ:RNA) released its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.68) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.68). The biotechnology company earned $2.16 million during the quarter, compared to analyst estimates of $1.50 million. Avidity Biosciences had a negative trailing twelve-month return on equity of 40.82% and a negative net margin of 1,886.33%.

ETFs with the largest weight of Avidity Biosciences (NASDAQ:RNA) stock in their portfolio include Direxion mRNA ETF (MSGR), Direxion Moonshot Innovators ETF (MOON), Alger 35 ETF (ATFV), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Invesco Raymond James SB-1 Equity ETF (RYJ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).

(RNA) raised $150 million in an IPO on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO.

Avidity Biosciences trades on the NASDAQ under the ticker symbol "RNA."

Avidity Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (12.32%), RA Capital Management L.P. (10.02%), Cowen AND Company LLC (7.87%), Avidity Partners Management LP (6.01%), Avoro Capital Advisors LLC (3.76%) and Artisan Partners Limited Partnership (2.39%). Insiders that own company stock include Arthur A Levin, Rtw Investments, Lp and Sarah Boyce.
View institutional ownership trends.

Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RNA stock can currently be purchased for approximately $15.35.

Avidity Biosciences (NASDAQ:RNA) has a market capitalization of $1.09 billion and generates $9.22 million in revenue each year. The biotechnology company earns $-173,990,000.00 in net income (profit) each year or ($3.33) on an earnings per share basis.

The company employs 125 workers across the globe.

Avidity Biosciences' mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The official website for the company is www.aviditybiosciences.com. The biotechnology company can be reached via phone at 858-401-7900 or via email at amy@juniper-point.com.